Abiomed (NSDQ:ABMD) today announced that the FDA has granted breakthrough device designation for its Impella ECP expandable percutaneous heart pump. Danvers, Mass.-based Abiomed designed the Impella ECP heart pump to be compatible with small-bore access and closure techniques. It measures 3 mm in diameter when inserted and removed from the body. It expands in the heart […]
Abiomed
MedTech 100 roundup: Industry ticks up again
The medtech industry has been rising for weeks and the latest seven-day stretch was no exception as stocks ticked up again. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 6) at 119.41 points, marking a 0.5% rise from the previous week’s tally of 118.86 […]
Abiomed beats The Street in Q1, boosts full-year revenue guidance
Abiomed (NASDAQ: ABMD) posted first-quarter results that beat the consensus forecast on Wall Street, with the company boosting its revenue growth forecast to 22–24% for the fiscal year. The Danvers, Mass.–based maker of circulatory and oxygenation support devices reported a loss of –$26.5 million, or –59¢ per share, on sales of $252.5 million for the […]
FDA grants PMA to Abiomed’s next-generation Impella RP
Abiomed (NSDQ:ABMD) announced today that the FDA granted premarket approval (PMA) to its Impella RP with SmartAssist. Danvers, Mass.–based Abiomed received PMA for the Impella RP right heart pump with SmartAssist as a safe and effective treatment for acute right heart failure for up to 14 days, according to a news release. The company touts […]
MedTech 100 roundup: Rebound hits a snag
Two weeks ago, medtech was on the rise following a rough stretch, but the past week brought the industry slightly back down to earth. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 4) at 106.96 points, producing a -1.4% dip from the 108.5-point mark […]
Abiomed buys PreCardia and its heart failure treatment system
Abiomed (NASDAQ: ABMD) announced this week that it has acquired PreCardia and its catheter-based system to treat acute decompensated heart failure. The financial terms of the deal were not disclosed in the June 1 announcement. Abiomed officials say the deal complements the company’s product portfolio, expanding options for patients with acute decompensated heart failure. The […]
MedTech 100 roundup: Return to normal following recent spike
After back-to-back all-time best performances, the medtech industry had a slight regression over the course of the last week. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — had been continuously ticking up since the beginning of April, with its mark of 112.25 on April 16 representing an all-time […]
Abiomed stock falls on Q4 results
Abiomed (NSDQ:ABMD) stock is recovering slightly today — a day after its stock fell on fourth-quarter results. ABMD shares were up 0.4% at $324.18 per share in mid-morning trading today, rebounding from a -8% slide to $322.94 per share upon the release of the earnings report yesterday. MassDevice’s MedTech 100 Index — which includes stocks […]
Abbott halts heart pump trial
Abbott (NYSE:ABT) has halted a clinical trial comparing its HeartMate percutaneous heart pump (PHP) ventricular assist device with the Abiomed (NSDQ:ABMD) Impella heart pumps. The Abbott Park, Ill.-based company suspended enrollment in the Shield II investigational device exemption study after a report of decreased impeller speed at the end of a procedure. The HeartMate PHP system […]
MedTech 100 Roundup: Small slide continues
On the back of several weeks of new records and strong performances, the medtech industry has finally hit a snag in its recent ascent. MassDevice‘s MedTech 100 index ended the week (Feb. 26) at 106.65 points, marking a 1.9% dip from the 108.72-point mark set one week before (Feb. 19). This highlights a similar drop from […]
DTW Podcast: Geoff Martha updates Medtronic’s new course; AJAX CEO Duke Rohlen is funding innovation differently
Less than a year into his role as CEO, Geoff Martha and the Medtronic leadership has overseen a significant reorganization of medtech’s largest player. In our closing keynote conversation, Martha says the company is clearing a minor COVID-19 bump and sees open road for the company to continue to grab share from competitors. Martha details […]
